We're here to help during Covid-19. Find out more here.
The reason for this study is to see if the study drug LY3484356 alone or in combination with abemaciclib is safe and effective in participants with advanced or metastatic breast cancer.
Who is it for?
You may be eligible for this study if you meet the below criteria:
Participants will be given either LY3484356 or LY3484356 with abemaciclib orally. Dosages will be escalated or expanded as the study goes on.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at firstname.lastname@example.org
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to email@example.com
Subscribe for updates & stay in the loop with new studies.